Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
7 June 2013 -- Universal Biosensors (ASX.UBI) has been presented with the ‘Technology in Manufacturing Award’ at this year’s Victorian Manufacturing Hall of Fame awards, honouring Victoria’s most inventive, productive and resilient manufacturers.
“We are extremely proud to receive this award and thank the Victorian Government for their support and encouragement over many years. Our world-class manufacturing facility in Rowville has solidly anchored our business in Victoria and provides an important platform for future growth,” said Paul Wright, CEO of Universal Biosensors.
The Technology in Manufacturing award recognises a Victorian company that has embraced enabling and emerging technologies within their manufacturing operations.
UBI is a leading player in the point-of-care diagnostics market, and has partnerships with two of the largest healthcare companies in the world – Siemens Healthcare Diagnostics and LifeScan (a subsidiary of Johnson & Johnson). The company’s core technology is a disposable biosensor test strip which uses its proprietary electrochemical sensors to rapidly and accurately test for components in the blood.
UBI’s world-class, highly automated manufacturing plant in Rowville employs more than 100 people and has the capacity to produce over 750 million glucose test strips per annum. The high-tech, high volume manufacturing plant is a source of competitive advantage and ongoing revenue.
The Victorian Manufacturing Hall of Fame awards are managed by the Department of State Development, Business and Innovation, and were held at Crown Casino in Melbourne on 6 June 2013.
The Victorian Government announcement is available to view here.
Mr Paul Wright: 03 9213 9000
About Universal Biosensors
For additional information in relation to Universal Biosensors, refer to
Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.
The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.
Help employers find you! Check out all the jobs and post your resume.